Alternatives to the Streptozotocin-Diabetic Rodent

International Review of Neurobiology

Volumn 127, Issue , 2016, Pages 89-112

  Yorek, M A ^a,b,c  

^a Iowa City Veterans Affairs Health Care Center   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Diabetes; Hyperglycemia; Mice; Nerve conduction velocity; Obesity; Peripheral diabetic neuropathy; Rats

Indexed keywords

AKITA MOUSE; BIOBREEDING RAT; BIOBREEDING ZUCKER DIABETIC RAT; C57BL 6 MOUSE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DB/DB MOUSE; DIABETIC NEUROPATHY; DISEASE COURSE; DISEASE MODEL; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; GOTO KAKIZAKI RAT; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONOBESE DIABETIC MOUSE; OB/OB MOUSE; OBESITY; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SCREENING; SPONTANEOUSLY DIABETIC TORII RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT; STREPTOZOTOCIN NICOTINAMIDE RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TSUMURA SUZUKI OBESE DIABETES MOUSE; ZUCKER DIABETIC FATTY RAT; ZUCKER RAT; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; DIABETIC NEUROPATHIES; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; HUMAN; NERVE CONDUCTION; PATHOLOGY; PATHOPHYSIOLOGY; RODENT;

ANTINEOPLASTIC ANTIBIOTIC; STREPTOZOCIN;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; HUMANS; NEURAL CONDUCTION; RODENTIA; STREPTOZOCIN;

EID: 84978121112     PISSN: 00747742     EISSN: 21625514     Source Type: Book Series    
DOI: 10.1016/bs.irn.2016.03.002     Document Type: Chapter

References (135)

1. Akash M.S., Rehman K., Chen S. Goto-Kakizaki rats: Its suitability as non-obese diabetic animal model for spontaneous type 2 diabetes mellitus. Current Diabetes Reviews 2013, 9:387-396.
2. Alderson N.L., Chachich M.E., Youssef N.N., Beattie R.J., Nachtigal M., Thorpe S.R., et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney International 2003, 63:2123-2133.
3. Anderson N.J., King M.R., Delbruck L., Jolivalt C.G. Role of insulin signaling impairment, adiponectin and dyslipidemia in peripheral and central neuropathy in mice. Disease Models & Mechanisms 2014, 7:625-633.
4. Asghar O., Petropoulos I.N., Alam U., Jones W., Jeziorska M., Marshall A., et al. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care 2014, 37:2643-2646.
5. Bansal P., Paul P., Mudgal J., Nayak P., Pannakal S., Priyadarsini K., et al. Antidiabetic, antihyperlipidemic and antioxidant effects of the flavonoid rich fraction of Pilea microphylla (L.) in high fat diet/streptozotocin-induced diabetes in mice. Experimental and Toxicologic Pathology 2012, 64:651-658.
6. Beltowski J. Leptin and the regulation of endothelial function in physiological and pathological conditions. Clinical and Experimental Pharmacology and Physiology 2012, 39:168-178.
7. Biessels G.J., Bril V., Calcutt N.A., Cameron N.E., Cotter M.A., Dobrowsky R., et al. Phenotyping animal models of diabetic neuropathy: A consensus statement of the diabetic neuropathy study group of the EASD (Neurodiab). Journal of the Peripheral Nervous System 2014, 19:77-87.
8. Bour-Jordan H., Thompson H.L., Giampaolo J.R., Davini D., Rosenthal W., Bluestone J.A. Distinct genetic control of autoimmune neuropathy and diabetes in the non-obese diabetic background. Journal of Autoimmunity 2013, 45:58-67.
9. Bray G.A. The Zucker-fatty rat: A review. Federation Proceedings 1977, 36:148-153.
10. Calcutt N.A. Modeling diabetic sensory neuropathy in rats. Methods in Molecular Medicine 2004, 99:55-65.
11. Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012, 6:CD007543.
12. Cameron N.E., Cotter M.A., Archibald V., Dines K.C., Maxfield E.K. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994, 37:449-459.
13. Cameron N.E., Cotter M.A., Dines K.C., Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1992, 35:946-950.
14. Cameron N.E., Cotter M.A., Dines K.C., Maxfield E.K., Carey F., Mirrlees D.J. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 1994, 37:651-663.
15. Cameron N.E., Cotter M.A., Low P.A. Nerve blood flow in early experimental diabetes in rats: Relation to conduction deficits. American Journal of Physiology. Endocrinology and Metabolism 1991, 261:E1-E8.
16. Cho Y.R., Lim J.H., Kim M.Y., Kim T.W., Hong B.Y., Kim Y.S., et al. Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice. PLoS One 2014, 9:e83204.
17. Cohen R.A., Tesfamariam B., Weisbrod R.M., Zitnay K.M. Adrenergic denervation in rabbits with diabetes mellitus. American Journal of Physiology. Heart and Circulatory Physiology 1990, 259:H55-H61.
18. Coppey L.J., Davidson E.P., Dunlap J.A., Lund D.D., Yorek M.A. Slowing of motor nerve conduction velocity in streptozotocin-induced diabetic rats is preceded by impaired vasodilation in arterioles that overlie the sciatic nerve. International Journal of Experimental Diabetes Research 2000, 1:131-143.
19. Coppey L., Davidson E., Lu B., Gerard C., Yorek M. Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice. Neuropharmacology 2011, 60:259-266.
20. Coppey L.J., Gellett J.S., Davidson E.P., Dunlap J.A., Yorek M.A. Changes in endoneurial blood flow, motor nerve conduction velocity and vascular relaxation of epineurial arterioles of the sciatic nerve in ZDF-obese diabetic rats. Diabetes/Metabolism Research and Reviews 2002, 18:49-56.
21. Cotter M.A., Dines K.C., Cameron N.E. Prevention and reversal of motor and sensory peripheral nerve conduction abnormalities in streptozotocin-diabetic rats by the prostacyclin analogue iloprost. Naunyn Schmiedeberg's Archives of Pharmacology 1993, 347:534-540.
22. Davidson E.P., Coppey L.J., Calcutt N.A., Oltman C.L., Yorek M.A. Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction. Diabetes/Metabolism Research and Reviews 2010, 26:306-318.
23. Davidson E.P., Coppey L.J., Dake B., Yorek M.A. Effect of treatment of Sprague Dawley rats with AVE7688, enalapril, or candoxatril on diet-induced obesity. Journal of Obesity 2011, 2011. 686952.
24. Davidson E.P., Coppey L.J., Holmes A., Dake B., Yorek M.A. Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications. European Journal of Pharmacology 2011, 668:497-506.
25. Davidson E.P., Coppey L.J., Holmes A., Lupachyk S., Dake B.L., Oltman C.L., et al. Characterization of diabetic neuropathy in the Zucker diabetic Sprague-Dawley rat: A new animal model for type 2 diabetes. Journal of Diabetes Research 2014, 2014. 714273.
26. Davidson E.P., Coppey L.J., Kardon R.H., Yorek M.A. Differences and similarities in development of corneal nerve damage and peripheral neuropathy and in diet-induced obesity and type 2 diabetic rats. Investigative Ophthalmology and Visual Science 2014, 55:1222-1230.
27. Davidson E., Coppey L., Lu B., Arballo V., Calcutt N.A., Gerard C., et al. The roles of streptozotocin neurotoxicity and neural endopeptidase in murine experimental diabetic neuropathy. Experimental Diabetes Research 2009, 2009. 431980.
28. Davidson E.P., Kleinschmidt T.L., Oltman C.L., Lund D.D., Yorek M.A. Treatment of streptozotocin-induced diabetic rats with AVE7688, a vasopeptidase inhibitor: Effect on vascular and neural disease. Diabetes 2007, 56:355-362.
29. Davis J.E., Cain J., Banz W.J., Peterson R.G. Age-related differences in response to high-fat feeding on adipose tissue and metabolic profile in ZDSD rats. ISRN Obesity 2013, 2013. 584547.
30. de Preux Charles A.S., Verdier V., Zenker J., Peter B., Medard J.J., Kuntzer T., et al. Global transcriptional programs in peripheral nerve endoneurium and DRG are resistant to the onset of type 1 diabetic neuropathy in Ins2 mice. PLoS One 2010, 5:e10832.
31. Ding S.Y., Shen Z.F., Chen Y.T., Sun S.J., Liu Q., Xie M.Z. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacologica Sinica 2005, 26:575-580.
32. Drel V.R., Mashtalir N., Ilnytska O., Shin J., Li F., Lyzogubov V.V., et al. The leptin-deficient (ob/ob) mouse: A new animal model of peripheral neuropathy of type 2 diabetes and obesity. Diabetes 2006, 55:3335-3343.
33. Drel V.R., Pacher P., Stavniichuk R., Xu W., Zhang J., Kuchmerovska T.M., et al. Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice. International Journal of Molecular Medicine 2011, 28:629-635.
34. Estrella J.S., Nelson R.N., Sturges B.K., Vernau K.M., Williams D.C., LeCouteur R.A., et al. Endoneurial microvascular pathology in feline diabetic neuropathy. Microvascular Research 2008, 75:403-410.
35. Figueroa-Romero C., Sadidi M., Feldman E.L. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Review in Endocrine and Metabolic Disorders 2008, 9:301-314.
36. Gade W., Schmit J., Collins M., Gade J. Beyond obesity: The diagnosis and pathophysiology of metabolic syndrome. Clinical Laboratory Science 2010, 23:51-61.
37. Gaikwad A.B., Viswanad B., Ramarao P. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. Pharmacological Research 2007, 55:400-407.
38. Gao F., Zheng Z.M. Animal models of diabetic neuropathic pain. Experimental and Clinical Endocrinology and Diabetes 2014, 122:100-106.
39. Gregory J.A., Jolivalt C.G., Goor J., Mizisin A.P., Calcutt N.A. Hypertension-induced peripheral neuropathy and the combined effects of hypertension and diabetes on nerve structure and function in rats. Acta Neuropathologica 2012, 124:561-573.
40. Groover A.L., Ryals J.M., Guilford B.L., Wilson N.M., Christianson J.A., Wright D.E. Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice. Pain 2013, 154:2658-2667.
41. Gross V., Tank J., Partke H.J., Plehm R., Diedrich A., da Costa Goncalves A.C., et al. Cardiovascular autonomic regulation in non-obese diabetic (NOD) mice. Autonomic Neuroscience: Basic and Clinical 2008, 138:108-113.
42. Grote C.W., Groover A.L., Ryals J.M., Geiger P.C., Feldman E.L., Wright D.E. Peripheral nervous system insulin resistance in ob/ob mice. Acta Neuropathologica Communications 2013, 1:15. 10.1186/2051-5960-1-15.
43. Hounsom L., Tomlinson D.R. Does neuropathy develop in animal models?. Clinical Neuroscience 1997, 4:380-389.
44. Islam M.S. Animal models of diabetic neuropathy: Progress since 1960s. Journal of Diabetes Research 2013, 2013. 149452.
45. Jun J.Y., Ma Z., Segar L. Spontaneously diabetic Ins2(+/Akita): ApoE-deficient mice exhibit exaggerated hypercholesterolemia and atherosclerosis. American Journal of Physiology. Endocrinology and Metabolism 2011, 301:E145-E154.
46. Kamenov Z., Higashino H., Todorova M., Kajimoto N., Suzuki A. Physiological characteristics of diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats. Methods and Findings in Experimental and Clinical Pharmacology 2006, 28:13-18.
47. Kamiya H., Murakawa Y., Zhang W., Sima A.A. Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes/Metabolism Research and Reviews 2005, 21:448-458.
48. Kamiya H., Zhang W., Sima A.A. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Annals of Neurology 2004, 56:827-835.
49. Kamiya H., Zhang W., Sima A.A. Dynamic changes of neuroskeletal proteins in DRGs underlie impaired axonal maturation and progressive axonal degeneration in type 1 diabetes. Experimental Diabetes Research 2009, 2009. 793281.
50. Kannan M.A., Sarva S., Kandadai R.M., Paturi V.R., Jabeen S.A., Borgohain R. Prevalence of neuropathy in patients with impaired glucose tolerance using various electrophysiological tests. Neurology India 2014, 62:656-661.
51. Kaur J. A comprehensive review on metabolic syndrome. Cardiology Research and Practice 2014, 2014. 943162.
52. Kava R., Greenwood M.R.C., Johnson P.R. Zucker (fa/fa) rat. ILAR Journal 1990, 32:4-8.
53. Kawada T., Miyata S., Shimada T., Sanzen Y., Ito M., Hemmi C., et al. A study of cardiovascular function in Tsumura Suzuki obese diabetes, a new model mouse of type 2 diabetes. Biological and Pharmaceutical Bulletin 2010, 33:998-1003.
54. Kemmochi Y., Fukui K., Maki M., Kimura S., Ishii Y., Sasase T., et al. Metabolic disorders and diabetic complications in spontaneously diabetic Torii Lepr (fa) rat: A new obese type 2 diabetic model. Journal of Diabetes Research 2013, 2013. 948257.
55. Kim H., Kim J.J., Yoon Y.S. Emerging therapy for diabetic neuropathy: Cell therapy targeting vessels and nerves. Endocrine, Metabolic and Immune Disorders Drug Targets 2012, 12:168-178.
56. Kurtz T.W., Morris R.C., Pershadsingh H.A. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 1989, 13:896-901.
57. Li F., Abatan O.I., Kim H., Burnett D., Larkin D., Obrosova I.G., et al. Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiology of Disease 2006, 22:669-676.
58. Lin Y., Hu G., Li K., Zhao Y., Wei J., Zhen Y. The protection of Rhein lysinate to liver in diabetic mice induced by high-fat diet and streptozotocin. Archives of Pharmacal Research 2015, 38:885-892.
59. Lirk P., Flatz M., Haller I., Hausott B., Blumenthal S., Stevens M.F., et al. In Zucker diabetic fatty rats, subclinical diabetic neuropathy increases in vivo lidocaine block duration but not in vitro neurotoxicity. Regional Anesthesia and Pain Medicine 2012, 37:601-606.
60. Lirk P., Verhamme C., Boeckh R., Stevens M.F., ten Hoope W., Gerner P., et al. Effects of early and late diabetic neuropathy on sciatic nerve block duration and neurotoxicity in Zucker diabetic fatty rats. British Journal of Anesthesia 2015, 114:319-326.
61. Lizuka S., Suzuki W., Tabuchi M., Nagata M., Imamura S., Kobayashi Y., et al. Diabetic complications in a new animal model (TSOD mouse) of spontaneous NIDDM with obesity. Experimental Animals 2005, 54:71-83.
62. Lupachyk S., Watcho P., Hasanova N., Julius U., Obrosova I.G. Triglyceride, nonesterified fatty acids, and prediabetic neuropathy: Role for oxidative-nitrosative stress. Free Radical Biology and Medicine 2012, 52:1255-1263.
63. Lupachyk S., Watcho P., Obrosov A.A., Stavniichuk R., Obrosova I.G. Endoplasmic reticulum stress contributes to prediabetic peripheral neuropathy. Experimental Neurology 2013, 247:342-348.
64. Lv L., Wu S., Wang G., Zhang J., Pang J., Liu Z., et al. Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Phytotherapy Research 2010, 24:219-224.
65. Mali V., Ning R., Chen J., Yang X., Xu J., Palaniyandi S. Impairment of aldehyde dehydrogenase-2 by 4-hydroxy-2-nonenal adduct formation and cardiomyocyte hypertrophy in mice fed a high-fat diet and injected with low-dose streptozotocin. Experimental Biology and Medicine 2014, 239:610-618.
66. Mesangeau D., Laude D., Elghozi J.L. Early detection of cardiovascular autonomic neuropathy in diabetic pigs using blood pressure and heart rate variability. Cardiovascular Research 2000, 45:889-899.
67. Mizisin A.P., Nelson R.W., Sturges B.K., Vernau K.M., Lecouteur R.A., Williams D.C., et al. Comparable myelinated nerve pathology in feline and human diabetes mellitus. Acta Neuropathologica 2007, 113:431-442.
68. Morgan M.J., Vite C.H., Radhakrishnan A., Hess R.S. Clinical peripheral neuropathy associated with diabetes mellitus in 3 dogs. The Canadian Veterinary Journal 2008, 49:583-586.
69. Murakawa Y., Zhang W., Pierson C.R., Brismar T., Ostenson C.G., Efendic S., et al. Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes/Metabolism Research and Reviews 2002, 18:473-483.
70. Nakamura J., Hamada Y., Sakakibara F., Hara T., Wakao T., Mori K., et al. Physiological and morphometric analyses of neuropathy in sucrose-fed OLETF rats. Diabetes Research and Clinical Practice 2001, 51:9-20.
71. Negi G., Kumar A., Kaundal R.K., Gulati A., Sharma S.S. Functional and biochemical evidence indicating beneficial effect of melatonin and nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology 2010, 58:585-592.
72. Norido F., Canella R., Zanoni R., Gorio A. Development of diabetic neuropathy in the C57BL/Ks (db/db) mouse and its treatment with gangliosides. Experimental Neurology 1984, 83:221-232.
73. Nowicki M., Kosacka J., Serke H., Bluher M., Spanel-Borowski K. Altered sciatic nerve fiber morphology and endoneural microvessels in mouse models relevant for obesity, peripheral diabetic polyneuropathy, and the metabolic syndrome. Journal of Neuroscience Research 2012, 90:122-131.
74. Nukada H., Dyck P.J. Microsphere embolization of nerve capillaries and fiber degeneration. The American Journal of Pathology 1984, 115:275-287.
75. O'Brien P.D., Hur J., Hayes J.M., Backus C., Sakowski S.A., Feldman E.L. BTBR ob/ob mice as a novel diabetic neuropathy model: Neurological characterization and gene expression analyses. Neurobiology of Disease 2014, 73C:348-355.
76. O'Brien P.D., Sakowski S.A., Feldman E.L. Mouse models of diabetic neuropathy. ILAR Journal 2014, 54:259-272.
77. Obrosova I.G., Ilnytska O., Lyzogubov V.V., Pavlov I.A., Mashtalir N., Nadler J.L., et al. High-fat diet induced neuropathy of pre-diabetes and obesity: Effects of "healthy" diet and aldose reductase inhibition. Diabetes 2007, 56:2598-2608.
78. Obrosova I.G., Mabley J.G., Zsengeller Z., Charniauskaya T., Abatan O.I., Groves J.T., et al. Role for nitrosative stress in diabetic neuropathy: Evidence from studies with a peroxynitrite decomposition catalyst. FASEB Journal 2005, 19:401-403.
79. Oltman C.L., Coppey L.J., Gellett J.S., Davidson E.P., Lund D.D., Yorek M.A. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. American Journal of Physiology. Endocrinology and Metabolism 2005, 289:E113-E122.
80. Oltman C.L., Davidson E.P., Coppey L.J., Kleinschmidt T.L., Lund D.D., Adebara E.T., et al. Vascular and neural dysfunction in Zucker diabetic fatty rats: A difficult condition to reverse. Diabetes, Obesity and Metabolism 2008, 10:64-74.
81. Oltman C.L., Davidson E.P., Coppey L.J., Kleinschmidt T.L., Yorek M.A. Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction. Diabetes, Obesity and Metabolism 2009, 11:223-233.
82. Otto K.J., Wyse B.D., Cabot P.J., Smith M.T. Longitudinal study of painful diabetic neuropathy in the Zucker diabetic fatty rat model of type 2 diabetes: Impaired basal G-protein activity appears to underpin marked morphine hyposensitivity at 6 months. Pain Medicine 2011, 12:437-450.
83. Pande M., Hur J., Hong Y., Backus C., Hayes J.M., Oh S.S., et al. Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: A model of type 2 diabetes. Diabetes 2011, 60:1981-1989.
84. Papanas N., Vinik A.I., Ziegler D. Neuropathy in prediabetes: Does the clock start ticking early?. Nature Reviews. Endocrinology 2011, 7:682-690.
85. Papanas N., Ziegler D. Prediabetic neuropathy: Does it exist?. Current Diabetes Reports 2012, 12:376-383.
86. Peterson R.G., Jackson C.V., Zimmeran K., de Winter W., Huebert N., Hansen M.K. Characterization of the ZDSD rat: A translational model for the study of metabolic syndrome and type 2 diabetes. Journal of Diabetes Research 2015, 2015. 487816.
87. Peterson R.G., Shaw W.N., Neel M.A., Little L.A., Eichberg J. Zuckerdiabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. ILAR Journal 1990, 32:16-19.
88. Pop-Busui R., Sima A., Stevens M. Diabetic neuropathy and oxidative stress. Diabetes/Metabolism Research and Reviews 2006, 22:257-273.
89. Portha B., Giroix M.H., Tourrel-Cuzin C., Le-Stunff H., Movassat J. The GK rat: A prototype for the study of non-overweight type 2 diabetes. Methods in Molecular Biology 2012, 933:125-159.
90. Quattrini C., Tavakoli M., Jeziorska M., Kallinikos P., Tesfaye S., Finnigan J., et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 2007, 56:2148-2154.
91. Reed M.J., Meszaros K., Entes L.J., Claypool M.D., Pinkett J.G., Gadbois T.M., et al. A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat. Metabolism 2000, 49:1390-1394.
92. Rees D.A., Alcolado J.C. Animal models of diabetes mellitus. Diabetic Medicine 2005, 22:359-370.
93. Reinwald S., Peterson R.G., Allen M.R., Burr D.B. Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models. American Journal of Physiology. Endocrinology and Metabolism 2009, 296:E765-E774.
94. Ricci R., Bevilacqua F. The potential role of leptin and adiponectin in obesity: A comparative review. Veterinary Journal 2012, 191:292-298.
95. Robertson D.M., Sima A.A. Diabetic neuropathy in the mutant mouse [C57BL/ks(db/db)]: A morphometric study. Diabetes 1980, 29:60-67.
96. Sanada L.S., Tavares M.R., Sato K.L., Ferreira Rda S., Neubern M.C., Castania J.A., et al. Association of chronic diabetes and hypertension in sural nerve morphometry: An experimental study. Diabetology and Metabolic Syndrome 2015, 7:9.
97. Sasase T., Ohta T., Masuyama T., Yokoi N., Kakehashi A., Shinohara M. The spontaneously diabetic Torii rat: An animal model of nonobese type 2 diabetes with severe diabetic complications. Journal of Diabetes Research 2013, 2013. 976209.
98. Sasase T., Yokoi N., Pezzolesi M.G., Shinohara M. Animal models of diabetes and metabolic disease 2014. Journal of Diabetes Research 2015, 2015. 571809.
99. Sharma A.K., Sharma A., Kumari R., Kishore K., Sharma D., Srinivasan B.P., et al. Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats. Journal of Biomedical Research 2012, 26:200-210.
100. Shi T.J., Zhang M.D., Zeberg H., Nilsson J., Grunler J., Liu S.X., et al. Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:690-695.
101. Shinohara M., Masuyama T., Shoda T., Takahashi T., Katsuda Y., Komeda K., et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. International Journal of Experimental Diabetes Research 2000, 1:89-100.
102. Sima A.A. Pathological mechanisms involved in diabetic neuropathy: Can we slow the process?. Current Opinion in Investigational Drugs 2006, 7:324-337.
103. Sima A.A., Robertson D.M. Peripheral neuropathy in mutant diabetic mouse [C57BL/Ks (db/db)]. Acta Neuropathologica 1978, 41:85-89.
104. Sima A.A., Zhang W., Sugimoto K., Henry D., Li Z., Wahren J., et al. C-peptide prevents and improves chronic type 1 diabetic polyneuropathy in the BB/Wor rat. Diabetologia 2001, 44:889-897.
105. Sima A.A., Zhang W., Xu G., Sugimoto K., Guberski D., Yorek M.A. A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor rats and in type I diabetic BB/Wor rats. Diabetologia 2000, 43:786-793.
106. Skovso S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. Journal of Diabetes Investigation 2014, 5:349-358.
107. Smith A.G., Singleton J.R. Impaired glucose tolerance and neuropathy. The Neurologist 2008, 14:23-29.
108. Srinivasan K., Viswanad B., Asrat L., Kaul C.L., Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharmacological Research 2005, 52:313-320.
109. Stevens M.J., Li F., Drel V.R., Abatan O.I., Kim H., Burnett D., et al. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. The Journal of Pharmacology and Experimental Therapeutics 2007, 320:458-464.
110. Stevens M.J., Zhang W., Li F., Sima A.A. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. American Journal of Physiology. Endocrinology and Metabolism 2004, 287:E497-E505.
111. Sullivan K.A., Hayes J.M., Wiggin T.D., Backus C., Su Oh S., Lentz S.I., et al. Mouse models of diabetic neuropathy. Neurobiology of Disease 2007, 28:276-285.
112. Szkudelski T. Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Experimental Biology and Medicine 2012, 237:481-490.
113. Taborsky G.J., Mei Q., Hackney D.J., Figlewicz D.P., LeBoeuf R., Mundinger T.O. Loss of islet sympathetic nerves and impairment of glucagon secretion in the NOD mouse: Relationship to invasive insulitis. Diabetologia 2009, 52:2602-2611.
114. Terata K., Coppey L.J., Davidson E.P., Dunlap J.A., Gutterman D., Yorek M.A. Acetylcholine-induced arteriolar dilation is reduced in streptozotocin-induced diabetic rats with motor nerve dysfunction. British Journal of Pharmacology 1999, 128:837-843.
115. Tesch G.H., Allen T.J. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology 2007, 12:261-266.
116. Tirabassi R.S., Flanagan J.F., Wu T., Kislauskis E.H., Birckbichler P.J., Guberski D.L. The BBZDR/Wor rat model for investigating the complications of type 2 diabetes mellitus. ILAR Journal 2004, 45:292-302.
117. +-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats. Life Sciences 2005, 76:2655-2668.
118. Ullevig S., Zhao Q., Zamora D., Asmis R. Ursolic acid protects diabetic mice against monocyte dysfunction and accelerated atherosclerosis. Atherosclerosis 2011, 219:409-416.
119. Vareniuk I., Pavlov I.A., Drel V.R., Lyzogubov V.V., Ilnystska O., Bell S.R., et al. Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice. Experimental Neurology 2007, 205:425-436.
120. Wada R., Koyama M., Mizukami H., Odaka H., Ikeda H., Yagihashi S. Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: A genetic model for type 2 diabetes. Diabetes/Metabolism Research and Reviews 1999, 15:332-337.
121. Wang F., Gao N., Yin J., Yu F.S. Reduced innervation and delayed re-innervation after epithelial wounding in type 2 diabetic Goto-Kakizaki rats. The American Journal of Pathology 2012, 181:2058-2066.
122. Wang Z., Hsu C., Lin H., Chen J. Antidiabetic effects of Carassius auratus complex formula in high fat diet combined streptozotocin-induced diabetic mice. Evidence Based Complementary and Alternative Medicine 2014, 2014. 628473.
123. Wang B., Li Y., Liu X., Liu S., Sun C. Effect of the duration of high-fat diet and the dosage of streptozotocin on establishing experimental animal model of type 2 diabetes mellitus. Wei Sheng Yan Jiu 2011, 40:99-102.
124. Wang C., Li J., Lv X., Zhang M., Song Y., Chen L., et al. Ameliorative effect of berberine on endothelial dysfunction in diabetic rats induced by high-fat diet and streptozotocin. European Journal of Pharmacology 2009, 620:131-137.
125. Whalen B.J., Mordes J.P., Rossini A.A. The BB rat as a model of human insulin-dependent diabetes mellitus. Current Protocols in Immunology 2001, (Suppl. 19). Chapter 15, 15.3.1-15.3.15.
126. +/myo-inositol cotransporter in diabetic rats. Kidney International 1996, 50:1202-1211.
127. Xue J., Ding W., Liu Y. Anti-diabetic effects of emodin involved in the activation of PPAR gamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice. Fitoterapia 2010, 81:173-177.
128. Yaguchi M., Nagashima K., Izumi T., Okamoto K. Neuropathological study of C57BL/6Akita mouse, type 2 diabetic model: Enhanced expression of alphaB-crystallin in oligodendrocytes. Neuropathology 2003, 23:44-50.
129. Yamaguchi T., Sasase T., Mera Y., Tomimoto D., Tadaki H., Kemmochi Y., et al. Diabetic peripheral neuropathy in spontaneously diabetic Torii-Lepr (fa) (SDT fatty) rats. The Journal of Veterinary Medical Science 2012, 74:1669-1673.
130. Yang B., Chon K.H. Assessment of diabetic cardiac autonomic neuropathy in type 1 diabetic mice 2011, 6560-6563.
131. Yorek M.S., Obrosov A., Shevalye H., Holmes A., Harper M.M., Kardon R.H., et al. Effect of diet-induced obesity or type 1 or type 2 diabetes on corneal nerves and peripheral neuropathy in C57Bl/6J mice. Journal of the Peripheral Nervous System 2015, 20:24-31.
132. Zhang M., Lv X.Y., Li J., Xu Z.G., Chen L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Experimental Diabetes Research 2008, 2008. 704045.
133. Zhang W., Yorek M., Pierson C.R., Murakawa Y., Breidenbach A., Sima A.A. Human C-peptide dose dependently prevents early neuropathy in the BB/Wor rat. International Journal of Experimental Diabetes Research 2001, 2:187-193.
134. Zhu N., Liu B., Luo W., Zhang Y., Li H., Li S., et al. Vasoconstrictor role of cyclooxygenase-1-mediated prostacyclin synthesis in non-insulin-dependent diabetic mice induced by high-fat diet and streptozotocin. American Journal of Physiology. Heart and Circulatory Physiology 2014, 307:H319-H327.
135. Zhu C.F., Peng H.B., Liu G.Q., Zhang F., Li Y. Beneficial effects of oligopeptides from marine salmon skin in a rat model of type 2 diabetes. Nutrition 2010, 26:1014-1020.